# A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B

> **NCT03075670** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 15 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia B

## Interventions

- **DRUG:** N9-GP
- **DRUG:** ALPROLIX®

## Key facts

- **NCT ID:** NCT03075670
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-07
- **Primary completion:** 2017-12-08
- **Final completion:** 2017-12-08
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03075670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03075670, "A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03075670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*